mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is a critical problem in the treatment of EGFR mutant lung cancer. Several mechanisms, including bypass signaling by hepatocyte growth factor (HGF)-triggered Met activation, are implicated...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daisuke Ishikawa, Shinji Takeuchi, Takayuki Nakagawa, Takako Sano, Junya Nakade, Shigeki Nanjo, Tadaaki Yamada, Hiromichi Ebi, Lu Zhao, Kazuo Yasumoto, Takahiro Nakamura, Kunio Matsumoto, Hiroshi Kagamu, Hirohisa Yoshizawa, Seiji Yano
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2a4ca02dcdca49eb800aab4aeeb60dfd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Ejemplares similares